Ponatinib
Non-Small Cell Lung Cancer, Head and Neck Cancer
Dana-Farber Cancer InstituteSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Non-Small Cell Lung Cancer, Head and Neck Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Same molecule, other indications
Ponatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →